Related Experiment Video
Updated: Jul 9, 2025
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody
Kristina E Atanasoff1,2, Luca Brambilla1,2, Daniel C Adelsberg1
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Importance:
The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.
Insights
Developing broadly effective therapeutics is crucial for combating emerging SARS-CoV-2 variants. This study characterized a neutralizing antibody, providing a workflow to predict therapeutic efficacy against new variants and guide vaccine development.
Area of Science:
- Virology
- Immunology
- Structural Biology
Background:
- The COVID-19 pandemic necessitates the development of broadly effective therapeutics against emerging SARS-CoV-2 variants.
- Neutralizing monoclonal antibodies are a key therapeutic strategy, but their efficacy depends on recognizing circulating viral variants.
Purpose of the Study:
- To characterize the epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone.
- To assess the antibody's effectiveness against multiple SARS-CoV-2 variants of concern.
Main Methods:
- Generation of antibody-resistant SARS-CoV-2 virions.
- Cryo-electron microscopy (cryo-EM) structural analysis.
- Vesicular stomatitis virus (VSV)-spike neutralization assays.
Main Results:
- Detailed characterization of the antibody's epitope and binding specificity.
- Demonstration of the antibody's efficacy against various SARS-CoV-2 variants.
- Validation of a workflow for predicting antibody efficacy.
Conclusions:
- The characterized antibody provides insights into neutralizing mechanisms against SARS-CoV-2 variants.
- The developed workflow can predict therapeutic efficacy and inform future vaccine and therapeutic design.
- This research aids in the ongoing fight against the COVID-19 pandemic.
